MET and glioma: Finally, to dissect tumor microenvironmental versus tumor-autonomous mechanisms in mediating the synergistic response of experimental gliomas to the combination of radiotherapy and tepotinib, we disrupted the Met gene in GL-261 glioma cells by CRISPR/Cas9 technology.